Q4 2025 Pelthos Therapeutics Inc Earnings Call Transcript
Key Points
- Pelthos Therapeutics Inc (PTHS) reported a 129% increase in prescriptions for its lead product, ZELSUVMI, from Q3 to Q4 2025, driving net product revenue growth from $7.1 million to $9.1 million.
- The company successfully acquired two FDA-approved products, XEPI and XEGLYZE, which are complementary to ZELSUVMI and expected to enhance revenue growth.
- Pelthos bolstered its financial position with an $18 million convertible note and a $15 million term debt loan, strengthening its cash balance and supporting its path to cash flow generation.
- ZELSUVMI has strong patent protection until 2035, with potential extension to 2037, providing a long runway for revenue growth.
- The company achieved a 59% coverage rate for commercial insurance plans and a 99% coverage rate for Medicaid, facilitating access to ZELSUVMI for patients.
- Pelthos Therapeutics Inc (PTHS) faces increased gross-to-net discounts, expected to rise to the mid to upper 30% range due to higher Medicaid usage and PBM contracts.
- The company anticipates rising SG&A expenses in 2026 due to the expansion of the sales team and preparation for the launch of XEPI and XEGLYZE.
- Despite revenue growth, Pelthos reported a net operating loss of $12.0 million in Q4 2025, though improved from a $15.4 million loss in Q3.
- The company is still early in the launch of ZELSUVMI and has not provided discrete revenue and EPS guidance, indicating uncertainty in future financial performance.
- Pelthos faces competitive dynamics in the market, with the need to differentiate ZELSUVMI as a first-line treatment option against in-office treatments.
Good morning everyone and welcome to Pelthos Therapeutics 2025, fourth quarter and fiscal year financial results conference call. Pelthos issued a press release today announcing its financial results for the year ending December 31, 2025. A copy can be found in the investor relations tab on the corporate website.
At www.pelthos.com. Before we begin, I'd like to remind you that during today's call, statements about the company's future expectations, plans, and prospects are forward-looking statements. These forward-looking statements are based on management's current expectations.
These statements are neither promises nor guarantees and involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from our current expectations expressed or implied by the forward-looking statements. Any such forward-looking statements represent management's estimates as of the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
